Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparing Intravenous Versus Nebulized Either Lidocaine or Dexmedetomidine for Attenuation of the Hemodynamic Responses to Laryngoscopy and Intubation

Next Previous
Trial Profile

Comparing Intravenous Versus Nebulized Either Lidocaine or Dexmedetomidine for Attenuation of the Hemodynamic Responses to Laryngoscopy and Intubation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexmedetomidine (Primary) ; Lidocaine (Primary) ; Dexmedetomidine; Lidocaine
  • Indications General anaesthesia
  • Focus Therapeutic Use

Most Recent Events

  • 25 Feb 2024 Status changed from active, no longer recruiting to completed.
  • 09 Jan 2024 Planned End Date changed from 10 Jan 2024 to 1 Jan 2024.
  • 23 Dec 2023 Planned primary completion date changed from 12 Dec 2023 to 23 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top